DelveInsight’s “Acromegaly Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Acromegaly, offering comprehensive insights into the Acromegaly revenue trends, prevalence, and treatment landscape. The report delves into key Acromegaly statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Acromegaly therapies. Additionally, we cover the landscape of Acromegaly clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Acromegaly treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Acromegaly space.

To Know in detail about the Acromegaly market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acromegaly Market Forecast

Some of the key facts of the Acromegaly Market Report: 

• The Acromegaly market size was valued ~USD 1,300 million in 2023 and  is to grow with a significant CAGR during the study period (2020-2034)

• In September 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today revealed that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist being developed for the proposed treatment and long-term maintenance therapy of acromegaly.

• In July 2024, Swedish pharmaceutical company Camurus announced positive outcomes from the Phase III ACROINNOVA 2 study, which evaluated the efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with acromegaly.

• In 2023, the total acromegaly market size in the United States was approximately USD 700 million.

• In 2023, somatostatin therapies generated the largest market size among all acromegaly treatments in the United States, reaching around USD 500 million, followed by growth hormone antagonists at approximately USD 160 million.

• In 2023, somatostatin therapies generated the highest revenue among all treatments in the EU4 and the UK, totaling approximately USD 300 million, followed by growth hormone antagonists at around USD 90 million.

• In the EU4 countries and the UK, the UK accounted for the largest share of the acromegaly market, contributing around 30% of the total market size in these regions.

• Key Acromegaly Companies: Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus AB, Ionis Pharmaceuticals, Ipsen, and others.

• Key Acromegaly Therapies: MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel®, and others.

• The Acromegaly market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acromegaly pipeline products will significantly revolutionize the Acromegaly market dynamics.

• In 2023, the United States had the highest number of diagnosed prevalent cases of acromegaly in the 7MM, with approximately 27,000 cases, followed by Japan with around 9,000 cases.

• In the United States, gender-specific cases of acromegaly in 2023 were approximately 13,000 in males and around 14,000 in females.

• In the US, tumor size-specific cases of acromegaly in 2023 were approximately 75% for macroadenomas and 25% for microadenomas, with numbers expected to rise.

• In the EU4 and the UK, tumor origin-specific cases of acromegaly in 2023 included approximately 20,300 cases from pituitary tumors and around 1,060 cases from non-pituitary tumors.

Acromegaly Overview

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland produces too much growth hormone (GH), typically due to a benign tumor called a pituitary adenoma. This excess GH causes abnormal growth of bones and tissues, leading to enlarged hands, feet, and facial features. Symptoms can develop slowly over years, often resulting in delayed diagnosis. If untreated, acromegaly can lead to serious health complications, including diabetes, hypertension, arthritis, and cardiovascular disease. Treatments include surgery, medication, and radiation therapy to reduce GH levels and manage symptoms.

Get a Free sample for the Acromegaly Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/acromegaly-market

Acromegaly Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acromegaly Epidemiology Segmentation: 

The Acromegaly market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Acromegaly

• Prevalent Cases of Acromegaly by severity

• Gender-specific Prevalence of Acromegaly

• Diagnosed Cases of Episodic and Chronic Acromegaly

Download the report to understand which factors are driving Acromegaly epidemiology trends @ Acromegaly Epidemiology Forecast 

Acromegaly Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acromegaly market or expected to get launched during the study period. The analysis covers Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug.  Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acromegaly Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acromegaly Therapies and Key Companies

• MYCAPSSA (octreotide acetate): Amryt Pharma/Chiasma

• SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals

• Paltusotine (CRN 00808): Crinetics Pharmaceuticals

• CAM2029 (octreotide subcutaneous depot): Camurus AB

• GHR-LRX: Ionis Pharmaceuticals

• Lanreotide A Autogel®: Ipsen

Discover more about therapies set to grab major Acromegaly market share @ Acromegaly Treatment Landscape

Acromegaly Market Drivers

• Increasing Awareness and Diagnosis

• Advances in Treatment Options

• Rising Incidence

• Improved Healthcare Access

• Government and Regulatory Support

• Research and Development Investments

Acromegaly Market Barriers

• High Treatment Costs

• Diagnostic Challenges

• Limited Patient Pool

• Side Effects of Current Therapies

• Lack of Awareness in Low-income Regions

• Limited Availability of Specialized Care 

Scope of the Acromegaly Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acromegaly Companies: Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus AB, Ionis Pharmaceuticals, Ipsen, and others

• Key Acromegaly Therapies: MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel®, and others

• Acromegaly Therapeutic Assessment: Acromegaly current marketed and Acromegaly emerging therapies

• Acromegaly Market Dynamics: Acromegaly market drivers and Acromegaly market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Acromegaly Unmet Needs, KOL’s views, Analyst’s views, Acromegaly Market Access and Reimbursement 

To know more about Acromegaly companies working in the treatment market, visit @ Acromegaly Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Acromegaly Market Report Introduction

2. Executive Summary for Acromegaly

3. SWOT analysis of Acromegaly

4. Acromegaly Patient Share (%) Overview at a Glance

5. Acromegaly Market Overview at a Glance

6. Acromegaly Disease Background and Overview

7. Acromegaly Epidemiology and Patient Population

8. Country-Specific Patient Population of Acromegaly 

9. Acromegaly Current Treatment and Medical Practices

10. Acromegaly Unmet Needs

11. Acromegaly Emerging Therapies

12. Acromegaly Market Outlook

13. Country-Wise Acromegaly Market Analysis (2020–2034)

14. Acromegaly Market Access and Reimbursement of Therapies

15. Acromegaly Market Drivers

16. Acromegaly Market Barriers

17.  Acromegaly Appendix

18. Acromegaly Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/